Heart failure with preserved ejection fraction is the most frequent but commonly overlooked phenotype in patients on chronic hemodialysis.
HFPEF
echocardiography
end-stage renal disease
heart failure
high-output heart failure
Journal
Frontiers in cardiovascular medicine
ISSN: 2297-055X
Titre abrégé: Front Cardiovasc Med
Pays: Switzerland
ID NLM: 101653388
Informations de publication
Date de publication:
2023
2023
Historique:
received:
23
12
2022
accepted:
09
05
2023
medline:
16
6
2023
pubmed:
16
6
2023
entrez:
16
6
2023
Statut:
epublish
Résumé
Heart failure (HF) is a serious complication of end-stage kidney disease (ESKD). However, most data come from retrospective studies that included patients on chronic hemodialysis at the time of its initiation. These patients are frequently overhydrated, which significantly influences the echocardiogram findings. The primary aim of this study was to analyze the prevalence of heart failure and its phenotypes. The secondary aims were (1) to describe the potential of N-terminal pro-brain natriuretic peptide (NTproBNP) for HF diagnosis in ESKD patients on hemodialysis, (2) to analyze the frequency of abnormal left ventricular geometry, and (3) to describe the differences between various HF phenotypes in this population. We included all patients on chronic hemodialysis for at least 3 months from five hemodialysis units who were willing to participate, had no living kidney transplant donor, and had a life expectancy longer than 6 months at the time of inclusion. Detailed echocardiography together with hemodynamic calculations, dialysis arteriovenous fistula flow volume calculation, and basic lab analysis were performed in conditions of clinical stability. Excess of severe overhydration was excluded by clinical examination and by employing bioimpedance. A total of 214 patients aged 66.4 ± 14.6 years were included. HF was diagnosed in 57% of them. Among patients with HF, HF with preserved ejection fraction (HFpEF) was, by far, the most common phenotype and occurred in 35%, while HF with reduced ejection fraction (HFrEF) occurred only in 7%, HF with mildly reduced ejection fraction (HFmrEF) in 7%, and high-output HF in 9%. Patients with HFpEF differed from patients with no HF significantly in the following: they were older (62 ± 14 vs. 70 ± 14, HFpEF was by far the most common heart failure phenotype in patients on chronic hemodialysis and was followed by high-output HF. Patients suffering from HFpEF were older and had not only typical echocardiographic changes but also higher hydration that mirrored increased filling pressures of both ventricles than in those of patients without HF.
Identifiants
pubmed: 37324637
doi: 10.3389/fcvm.2023.1130618
pmc: PMC10267437
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1130618Informations de copyright
© 2023 Malik, Valerianova, Pesickova, Michalickova, Hladinova, Hruskova, Bednarova, Rocinova, Tothova, Kratochvilova, Kaiserova, Buryskova Salajova, Lejsek, Sevcik and Tesar.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Kidney Int. 1995 Mar;47(3):884-90
pubmed: 7752588
JACC Heart Fail. 2018 Aug;6(8):701-709
pubmed: 30007554
Front Cardiovasc Med. 2022 Jul 27;9:922593
pubmed: 35966517
Front Cardiovasc Med. 2021 Feb 22;8:646402
pubmed: 33693039
Cardiol Clin. 2011 Aug;29(3):447-59
pubmed: 21803232
Am J Kidney Dis. 2001 Nov;38(5):992-1000
pubmed: 11684552
Clin Res Cardiol. 2020 Aug;109(8):1035-1047
pubmed: 32002632
J Am Soc Nephrol. 2001 Dec;12(12):2759-2767
pubmed: 11729246
Heart Fail Rev. 2022 Sep;27(5):1857-1867
pubmed: 35043264
J Vasc Access. 2012 Jul-Sep;13(3):310-4
pubmed: 22266595
Eur Heart J Cardiovasc Imaging. 2013 Jul;14(7):611-44
pubmed: 23733442
Eur Heart J Cardiovasc Imaging. 2016 Apr;17(4):412
pubmed: 26983884
Am J Nephrol. 2021;52(2):108-118
pubmed: 33756478
Cardiorenal Med. 2019;9(3):190-200
pubmed: 30844787
J Vasc Access. 2018 Jan;19(1):3-11
pubmed: 29192719
Eur J Heart Fail. 2012 Aug;14(8):803-69
pubmed: 22828712
Int J Nephrol. 2011;2011:297070
pubmed: 21860794
Am J Kidney Dis. 2020 Aug;76(2):233-247
pubmed: 32387090
Am J Cardiovasc Dis. 2019 Oct 15;9(5):91-108
pubmed: 31763061
J Am Soc Nephrol. 2017 Aug;28(8):2491-2497
pubmed: 28473637
Kidney Int. 2004 Jun;65(6):2380-9
pubmed: 15149351
PLoS One. 2018 Apr 9;13(4):e0195202
pubmed: 29630661
J Vasc Access. 2022 Jun 8;:11297298221099843
pubmed: 35676802
ESC Heart Fail. 2021 Jun;8(3):2165-2171
pubmed: 33755355
Eur Heart J. 2011 Mar;32(6):670-9
pubmed: 21138935
Eur J Heart Fail. 2016 Aug;18(8):891-975
pubmed: 27207191
Am J Cardiol. 1990 Aug 15;66(4):493-6
pubmed: 2386120
Front Cardiovasc Med. 2021 Jun 15;8:684297
pubmed: 34212014
J Am Coll Cardiol. 2016 Aug 2;68(5):473-482
pubmed: 27470455
J Nephrol. 2002 Nov-Dec;15(6):655-60
pubmed: 12495279
Nephrol Dial Transplant. 1990;5(1):39-44
pubmed: 2109283
Kidney Blood Press Res. 2017;42(1):165-176
pubmed: 28395286
Front Cardiovasc Med. 2021 Jun 04;8:680098
pubmed: 34150871
J Card Fail. 2019 Jul;25(7):524-533
pubmed: 30844441
JAMA Cardiol. 2019 Apr 1;4(4):353-362
pubmed: 30892557
Eur J Heart Fail. 2022 Jan;24(1):4-131
pubmed: 35083827
Eur Heart J. 2019 Oct 21;40(40):3297-3317
pubmed: 31504452